Joshua Lin and Team: New Evidence on Long-Term Anticoagulation for Unprovoked VTE
Joshua Lin, Executive Director of Mass General Brigham Center for Integrated Healthcare Data Research, posted on LinkedIn:
”New Evidence on Long-Term Anticoagulation for Unprovoked VTE
We are pleased to share our recent BMJ publication demonstrating that continuation of oral anticoagulant therapy beyond the initial 90-day treatment period after a first unprovoked venous thromboembolism (VTE) is associated with a significantly lower risk of recurrent thrombosis and all-cause mortality, compared with early discontinuation. Extended therapy, however, is also associated with a higher risk of major bleeding – underscoring the importance of individualized clinical decision-making.
Full study here.
Press Release here.”
Title: Continued versus discontinued oral anticoagulant treatment for unprovoked venous thromboembolism: target trial emulation
Authors: Kueiyu Joshua Lin, Dae Hyun Kim, Daniel E Singer, Yichi Zhang, Alexander Cervone, Anna R Kehoe, Katsiaryna Bykov
Stay updated with Hemostasis Today.
-
Apr 14, 2026, 17:32Denise M.: Surviving Sepsis 2026 – The Upstream Revolution
-
Apr 14, 2026, 17:23Meghanath Yenni։ What’s New in Acute Ischemic Stroke in 2026
-
Apr 14, 2026, 17:11Phil Spinella: What Dose of TXA for Children With Severe Traumatic Bleeding Should You Use?
-
Apr 14, 2026, 17:08Abdulrahman Katib: How Endovascular Stenting Is Transforming the Treatment of Severe PTS
-
Apr 14, 2026, 17:00Anna A. Avagyan: Glad to Be Part of EHA Pediatric Hematology-Oncology Course
-
Apr 14, 2026, 16:58Ney Carter Borges: NLRP3 Inhibition in Atherosclerosis – Early Clinical Signal Beyond Lipids
-
Apr 14, 2026, 16:56Saskia Middeldorp: Key Takeaways from the 2026 ACC/AHA Guideline on Acute PE
-
Apr 14, 2026, 16:54Chokri Ben Lamine: Extracorporeal Photopheresis for aGVHD cGVHD Post-SCT – 50 Pearls
-
Apr 14, 2026, 16:49Ahmed Magdi Omar: Key Takeaways From the Latest 2026 Guidelines on Antiplatelet Therapy in AIS